A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Public ClinicalTrials.gov record NCT06748053. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicentre, Randomized, Double-Blind, Placebo Controlled, Dose Finding, Parallel Group, Phase 2 Study of an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.
Study identification
- NCT ID
- NCT06748053
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 307 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 10, 2025 (Actual)
- Primary completion
- Jul 14, 2026 (Actual)
- Completion
- Sep 9, 2027 (Estimated)
- Last update posted
- Aug 12, 2026
2025 – 2027
United States locations
- U.S. sites
- 51
- U.S. states
- 19
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Little Rock | Arkansas | 72205 | — |
| GSK Investigational Site | Long Beach | California | 90815 | — |
| GSK Investigational Site | Los Angeles | California | 90025 | — |
| GSK Investigational Site | Redding | California | 96001 | — |
| GSK Investigational Site | Riverside | California | 92506 | — |
| GSK Investigational Site | Sacramento | California | 95817 | — |
| GSK Investigational Site | San Jose | California | 95117 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80923 | — |
| GSK Investigational Site | Lakewood | Colorado | 80228-1813 | — |
| GSK Investigational Site | Wheat Ridge | Colorado | 80033 | — |
| GSK Investigational Site | New Haven | Connecticut | 06511 | — |
| GSK Investigational Site | Aventura | Florida | 33180 | — |
| GSK Investigational Site | Hialeah | Florida | 33012 | — |
| GSK Investigational Site | Lake Worth | Florida | 33460 | — |
| GSK Investigational Site | Leesburg | Florida | 34748 | — |
| GSK Investigational Site | Miami | Florida | 33144 | — |
| GSK Investigational Site | Miami | Florida | 33166 | — |
| GSK Investigational Site | Miami | Florida | 33172 | — |
| GSK Investigational Site | Miami | Florida | 33173 | — |
| GSK Investigational Site | Plantation | Florida | 33324 | — |
| GSK Investigational Site | Tampa | Florida | 33607 | — |
| GSK Investigational Site | Skokie | Illinois | 60077 | — |
| GSK Investigational Site | Shreveport | Louisiana | 71105 | — |
| GSK Investigational Site | Lathrup Village | Michigan | 48076 | — |
| GSK Investigational Site | Warren | Michigan | 48088 | — |
| GSK Investigational Site | St Louis | Missouri | 63119 | — |
| GSK Investigational Site | Omaha | Nebraska | 68198 | — |
| GSK Investigational Site | The Bronx | New York | 10461 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45236 | — |
| GSK Investigational Site | DuBois | Pennsylvania | 15801 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15241 | — |
| GSK Investigational Site | Wyomissing | Pennsylvania | 19610 | — |
| GSK Investigational Site | Warwick | Rhode Island | 02886 | — |
| GSK Investigational Site | Greenville | South Carolina | 29607 | — |
| GSK Investigational Site | Spartanburg | South Carolina | 29303 | — |
| GSK Investigational Site | Knoxville | Tennessee | 37909 | — |
| GSK Investigational Site | Boerne | Texas | 78006 | — |
| GSK Investigational Site | Cypress | Texas | 77429 | — |
| GSK Investigational Site | Dallas | Texas | 75225 | — |
| GSK Investigational Site | Houston | Texas | 77058 | — |
| GSK Investigational Site | Kerrville | Texas | 78028 | — |
| GSK Investigational Site | McKinney | Texas | 75069 | — |
| GSK Investigational Site | San Antonio | Texas | 78212 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Sherman | Texas | 75092 | — |
| GSK Investigational Site | American Fork | Utah | 84003 | — |
| GSK Investigational Site | Pleasant View | Utah | 84404 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84117 | — |
| GSK Investigational Site | South Ogden | Utah | 84405 | — |
| GSK Investigational Site | Bellingham | Washington | 98225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 83 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06748053, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 12, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06748053 live on ClinicalTrials.gov.